
By PR Newswire | Article Rating: |
|
September 3, 2014 07:49 PM EDT | Reads: |
253 |

SYDNEY, Sept. 3, 2014 /PRNewswire/ -- Novogen Ltd. (ASX: NRT, NASDAQ: NVGN) today announced that Graham Kelly PhD, CEO, will present at the Rodman & Renshaw 16th Annual Healthcare Conference on Wednesday, September 10th in New York. Dr. Kelly will provide an overview of the two Novogen first-in-class drug technology platforms in the field of oncology. His presentation will take place at the New York Palace Hotel and will begin at 10:25am.
About Novogen Limited
Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT-based joint venture company, CanTx Inc, with Yale University.
Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.
Further information is available on the Company's website, www.novogen.com.
For more information please contact:
Corporate Contact |
Media enquiries |
Executive Chairman & CEO |
In the USA: |
Lazar Partners | |
Investors enquiries |
In Australia: |
In the USA: Lazar Partners +1 212-867-1762 |
Dr. Douglas Pretsell Instinctif Partners +61 (0) 3 9657 0706 |
In ROW: | |
Sue Charles Instinctif Partners +44 (0) 20 7457 2020 |
Logo - http://photos.prnewswire.com/prnh/20131220/NY36990LOGO
SOURCE Novogen Ltd.
Published September 3, 2014 Reads 253
Copyright © 2014 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
More Stories By PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
![]() Apr. 26, 2018 10:00 PM EDT Reads: 5,358 |
By Elizabeth White ![]() Apr. 26, 2018 09:30 PM EDT Reads: 4,771 |
By Pat Romanski ![]() Apr. 26, 2018 09:30 PM EDT Reads: 4,347 |
By Elizabeth White ![]() Apr. 26, 2018 09:30 PM EDT Reads: 9,344 |
By Elizabeth White ![]() Apr. 26, 2018 09:30 PM EDT Reads: 5,655 |
By Liz McMillan ![]() Apr. 26, 2018 09:00 PM EDT Reads: 22,879 |
By Elizabeth White ![]() Apr. 26, 2018 09:00 PM EDT Reads: 5,250 |
By Liz McMillan ![]() Apr. 26, 2018 08:45 PM EDT Reads: 5,072 |
By Yeshim Deniz Apr. 26, 2018 08:00 PM EDT Reads: 2,851 |
By Elizabeth White ![]() Apr. 26, 2018 07:45 PM EDT Reads: 6,114 |
By Pat Romanski ![]() Apr. 26, 2018 07:30 PM EDT Reads: 5,212 |
By Liz McMillan ![]() Apr. 26, 2018 07:15 PM EDT Reads: 6,023 |
By Liz McMillan ![]() Apr. 26, 2018 07:00 PM EDT Reads: 13,983 |
By Elizabeth White ![]() Apr. 26, 2018 06:00 PM EDT Reads: 4,732 |
By Pat Romanski Apr. 26, 2018 06:00 PM EDT Reads: 6,518 |